Boryung Pharmaceutical received their first sales approval of hypertensive treatment 'Kanarb' in Mexico

Published: 2014-06-11 12:03:23

Updated: 2014-06-11 12:03:23

On May 27, Boryung Pharmaceutical announced that they received their first sales approval of hypertensive treatment 'Kanarb' from the COFEPRIS/The Federal Commission for the Protection against Sanitary Risk in Mexico.

According to the Boryung Pharmaceutical, they signed a licensing out contract of Kanarb with Stendhal and 13 countries in Latin America on last October 2011, and received sales a...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.